Home
/
Edwards Lifesciences Corp
/
Financials
/
Quarterly
Edwards Lifesciences Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Edwards Lifesciences Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.55B
Nov 5, 2025
Q2
2025
Jun 30, 2025
$1.53B
Aug 6, 2025
Q1
2025
Mar 31, 2025
$1.41B
May 6, 2025
Q3
2025
Sep 30, 2024
$1.35B
Nov 5, 2025
Q2
2025
Jun 30, 2024
$1.37B
Aug 6, 2025
Q1
2025
Mar 31, 2024
$1.33B
May 6, 2025
Q3
2024
Sep 30, 2023
$1.24B
Nov 6, 2024
Q2
2024
Jun 30, 2023
$1.30B
Jul 31, 2024
Q1
2024
Mar 31, 2023
$1.46B
Apr 29, 2024
Q3
2023
Sep 30, 2022
$1.32B
Oct 27, 2023
Q2
2023
Jun 30, 2022
$1.37B
Jul 28, 2023
Q1
2023
Mar 31, 2022
$1.34B
Apr 28, 2023
Q3
2022
Sep 30, 2021
$1.31B
Oct 28, 2022
Q2
2022
Jun 30, 2021
$1.38B
Jul 29, 2022
Q1
2022
Mar 31, 2021
$1.22B
Apr 28, 2022
Q3
2021
Sep 30, 2020
$1.14B
Oct 29, 2021
Q2
2021
Jun 30, 2020
$925.00M
Jul 30, 2021
Q1
2021
Mar 31, 2020
$1.13B
Apr 28, 2021
Q3
2020
Sep 30, 2019
$1.09B
Oct 26, 2020
Q2
2020
Jun 30, 2019
$1.09B
Jul 27, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$894.80M
Apr 27, 2018
Q3
2017
Sep 30, 2017
$821.50M
Oct 27, 2017
Q2
2017
Jun 30, 2017
$841.80M
Jul 28, 2017
Q1
2018
Mar 31, 2017
$883.50M
Apr 27, 2018
Q3
2017
Sep 30, 2016
$739.40M
Oct 27, 2017
Q2
2017
Jun 30, 2016
$759.30M
Jul 28, 2017
Q1
2017
Mar 31, 2016
$697.30M
Apr 28, 2017
Q3
2016
Sep 30, 2015
$615.50M
Oct 28, 2016
Q2
2016
Jun 30, 2015
$616.80M
Jul 29, 2016
Q1
2016
Mar 31, 2015
$590.30M
Apr 29, 2016
Q3
2015
Sep 30, 2014
$607.40M
Oct 29, 2015
Q2
2015
Jun 30, 2014
$575.10M
Jul 29, 2015
Q1
2015
Mar 31, 2014
$522.40M
Apr 29, 2015
Q3
2014
Sep 30, 2013
$495.60M
Oct 31, 2014
Q2
2014
Jun 30, 2013
$517.20M
Aug 4, 2014
Q1
2014
Mar 31, 2013
$496.70M
May 2, 2014
Q3
2013
Sep 30, 2012
$447.90M
Nov 7, 2013
Q2
2013
Jun 30, 2012
$482.00M
Aug 6, 2013
Q1
2013
Mar 31, 2012
$459.20M
May 6, 2013
Q3
2012
Sep 30, 2011
$412.70M
Nov 7, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$291.10M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$333.20M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$358.00M
May 6, 2025
Q3
2025
Sep 30, 2024
$3.07B
Nov 5, 2025
Q2
2025
Jun 30, 2024
$366.30M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$351.90M
May 6, 2025
Q3
2024
Sep 30, 2023
$384.90M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$307.10M
Jul 31, 2024
Q1
2024
Mar 31, 2023
$340.50M
Apr 29, 2024
Q3
2023
Sep 30, 2022
$343.50M
Oct 27, 2023
Q2
2023
Jun 30, 2022
$406.40M
Jul 28, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$307.10M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$411.20M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$394.80M
May 6, 2025
Q3
2025
Sep 30, 2024
$350.60M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$366.50M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$349.00M
May 6, 2025
Q3
2024
Sep 30, 2023
$365.90M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$263.50M
Jul 31, 2024
Q1
2024
Mar 31, 2023
$388.40M
Apr 29, 2024
Q3
2023
Sep 30, 2022
$402.40M
Oct 27, 2023
Q2
2023
Jun 30, 2022
$459.50M
Jul 28, 2023
Q1
2023
Mar 31, 2022
$438.80M
Apr 28, 2023
Q3
2022
Sep 30, 2021
$390.30M
Oct 28, 2022
Q2
2022
Jun 30, 2021
$542.10M
Jul 29, 2022
Q1
2022
Mar 31, 2021
$383.50M
Apr 28, 2022
Q3
2021
Sep 30, 2020
$357.80M
Oct 29, 2021
Q2
2021
Jun 30, 2020
($169.70M)
Jul 30, 2021
Q1
2021
Mar 31, 2020
$358.10M
Apr 28, 2021
Q3
2020
Sep 30, 2019
$294.30M
Oct 26, 2020
Q2
2020
Jun 30, 2019
$267.50M
Jul 27, 2020